Parikh Shruti, Bentz Taylor, Crowley Samuel, Greenspan Seth, Costa Ana, Bergese Sergio
Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
J Clin Med. 2025 May 30;14(11):3847. doi: 10.3390/jcm14113847.
Perioperative blood management strategies include evidence-based guidelines to efficiently manage blood products and transfusions while minimizing blood loss and improving patient outcomes. Perioperative Medicine has made evident that anemia is often under-recognized and not appropriately addressed prior to surgery. Early recognition and correction of anemia is imperative for better surgical optimization, fewer transfusions perioperatively, and improved outcomes. Patient blood management utilize evidence-based guidelines for the establishment of a framework to promote treatment of the causes of anemia, reduce blood loss and coagulopathy as well as to improve patient safety and outcomes by efficiently managing blood products, decrease complications associated with blood transfusions and reduce overall costs. Both liberal and restrictive strategies for blood transfusions established thresholds for hemoglobin: restrictive transfusion threshold of hemoglobin 7-8 g/dL in stable patients, and a higher transfusion threshold of hemoglobin > 8 g/dL may be considered in patients with cardiac disease. Intraoperatively, tests such as viscoelastic testing, including rotational thromboelastometry and thrombelastography, offer real-time analysis of a patient's clotting ability, allowing for targeted transfusions of fresh frozen plasma, platelets, cryoprecipitate or antifibrinolytic drugs. Complications associated with blood transfusions include allergic reactions, delayed hemolytic reactions, transfusion related acute lung injury, transfusion-associated circulatory overload, and the transmission of infectious diseases such as Hepatitis B, Hepatitis C, and Human-immunodeficiency virus. This review will discuss the management of blood products for surgical patients in the entire perioperative setting, with specific considerations for the peri-, intra- and post-operative stages.
围手术期血液管理策略包括基于证据的指南,以有效管理血液制品和输血,同时尽量减少失血并改善患者预后。围手术期医学已表明,贫血在术前往往未得到充分认识和适当处理。早期识别和纠正贫血对于更好地进行手术优化、减少围手术期输血以及改善预后至关重要。患者血液管理利用基于证据的指南建立一个框架,以促进对贫血病因的治疗,减少失血和凝血病,以及通过有效管理血液制品提高患者安全性和预后,减少与输血相关的并发症并降低总体成本。输血的宽松和限制性策略都设定了血红蛋白阈值:稳定患者的限制性输血阈值为血红蛋白7 - 8 g/dL,对于患有心脏病的患者,可考虑更高的输血阈值,即血红蛋白> 8 g/dL。在术中,诸如黏弹性检测等测试,包括旋转血栓弹力图和血栓弹力描记法,可实时分析患者的凝血能力,从而有针对性地输注新鲜冰冻血浆、血小板、冷沉淀或抗纤溶药物。与输血相关的并发症包括过敏反应、迟发性溶血反应、输血相关急性肺损伤、输血相关循环超负荷以及传染病的传播,如乙型肝炎、丙型肝炎和人类免疫缺陷病毒。本综述将讨论在整个围手术期对手术患者血液制品的管理,并对围手术期、术中和术后阶段进行具体考量。